Group One Trading’s Phathom Pharmaceuticals PHAT Stock Holding History

Group One Trading’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$151K	Sell	13,881 -3,058	-18%	-$34.9K	﹤0.01%	4522
2026 Q1	$188K	Sell	16,939 -86,745	-84%	-$1.1M	﹤0.01%	4157
2025 Q4	$1.72M	Buy	103,684 +99,436	+2,341%	+$1.42M	﹤0.01%	2406
2025 Q3	$50K	Buy	+4,248	New	+$43.8K	﹤0.01%	5964
2025 Q2	–	Sell	-2,404	Closed	-$13.3K	–	8491
2025 Q1	$15.1K	Buy	+2,404	New	+$14.6K	﹤0.01%	6004
2024 Q4	–	Sell	-15,130	Closed	-$187K	–	7804
2024 Q3	$274K	Buy	15,130 +7,762	+105%	+$108K	﹤0.01%	3345
2024 Q2	$75.9K	Buy	+7,368	New	+$75.9K	﹤0.01%	4180
2024 Q1	–	Sell	-1,545	Closed	-$13.1K	–	7755
2023 Q4	$14.1K	Buy	+1,545	New	+$13.3K	﹤0.01%	5980

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Group One Trading's PHAT Position: Q2 2026 in Review

Group One Trading reduced its Phathom Pharmaceuticals (PHAT) stake by 18% in Q2 2026, selling an estimated $34.9K and leaving 13,881 shares worth $151K. The position accounts for ﹤0.01% of the portfolio, ranked #4522.

Group One Trading first reported a position in PHAT in Q4 2023 and has held it in 8 quarters since. The position peaked at $1.72M in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

Group One Trading held 13,881 shares of Phathom Pharmaceuticals worth $151K as of Q2 2026.
Group One Trading sold 3,058 Phathom Pharmaceuticals shares in Q2 2026, an estimated $34.9K.
Phathom Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #4522 holding.
Group One Trading first reported a position in Phathom Pharmaceuticals in Q4 2023 and has held it in 8 quarters since.
Group One Trading's Phathom Pharmaceuticals position peaked at $1.72M in Q4 2025.
161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.